Pardoll is an inventor on patents licensed by BMS.With over 300 papers and 20 book chapters on the subjects of T cell immunology and cancer vaccines, he is a recognized expert in the field of immunology.Dr. Pardoll serves as the Director of the Bloomberg~Kimmel Institute for Cancer Immunotherapy and Co-Director of the Cancer Immunology Program at the Sidney Kimmel Comprehensive Cancer Center.Dr. Pardoll is also appointed as the Abeloff Professor of Oncology, Medicine, Pathology and Molecular Biology and Genetics at the Johns Hopkins University, School of Medicine.Complementing his academic pursuits, he founded Jounce Therapeutics, Inc. in 2012, is the Scientific Founder and Board Observer at Amplimmune, Inc., chairs the scientific advisory board of Aduro BioTech, Inc., and serves as a Director of DNAtrix, Inc.He was the first to propose blockade of PD-1 for cancer therapy, and his research led the clinical development of the first anti-PD-1 antibody.
Events - Primer's event detection algorithm clusters and summarizes multiple documents describing real-world events.
Mentions - Mentions are snippets of text that map to a person.
Docs - The number of documents that match to a person in Primer's corpus of news articles.
Full tech explainer here.
Remember to check the sources and follow Wikipedia's guidelines.
Bloomberg ~ Kimmel Institute for Cancer Immunotherapy
A drug given to early stage lung cancer patients before they undergo surgery showed major tumor responses in the removed tumor and an increase in anti-tumor T-cells that remained after the tumor was removed, which resulted in fewer relapse cases in the patients. The research teams at the, the Johns Hopkins Sidney Kimmel Cancer Center and the Memorial Sloan-Kettering Cancer Center wanted to find out if providing nivolumab, an anti-PD-1 drug, would stimulate anti-tumor immunity in patients with non-small-cell lung cancer who were going to have their tumors surgically removed. The research teams discovered new infiltration of immune cells into the lung cancer after the drug was administered. "Given that phase 3 clinical trials are underway, using this neoadjuvant anti-PD-1 drug will likely be practice changing," said Drew Pardoll, M.D., Ph.D., senior author, director of the Bloomberg-Kimmel Institute for Cancer Immunotherapy and co-director of the Cancer Immunology Program at the Kimmel Cancer Center.